Clinical Trials Logo

Filter by:
NCT ID: NCT03561675 Recruiting - Clinical trials for Acute Mountain Sickness

Effect of Acetazolamide on Acute Mountain Sickness in Lowlanders Older Than 40 Years

Start date: June 1, 2018
Phase: Phase 4
Study type: Interventional

Randomized, placebo controlled trial evaluating efficacy of acetazolamide in preventing acute mountain sickness in lowlanders older than 40 years travelling from 760 m to 3'100 m.

NCT ID: NCT03540914 Recruiting - Altitude Hypoxia Clinical Trials

Effect of Acetazolamide on Right Heart Function at Rest in Lowlanders Older Than 40 Years at Altitude.

Start date: June 1, 2018
Phase: Phase 4
Study type: Interventional

Randomized, placebo controlled trial evaluating efficacy of acetazolamide on right heart function at rest in lowlanders older than 40 years travelling from 760 m to 3'100 m.

NCT ID: NCT03540901 Recruiting - Clinical trials for Chronic Obstructive Pulmonary Disease

Effect of Acetazolamide on Lung Water Content by Ultrasound in Patients With Respiratory Disease at Altitude

Start date: May 22, 2018
Phase: Phase 4
Study type: Interventional

This trial will evaluate the effect of acetazolamide (375 mg per day) vs. placebo on lung water content by ultrasound at acute altitude exposure in patients with Chronic Obstructive Pulmonary Disease (COPD).

NCT ID: NCT03539367 Recruiting - Altitude Hypoxia Clinical Trials

Effect of Acetazolamide on Lung Water Content by Ultrasound in Lowlanders Older Than 40 Years at Altitude

Start date: June 1, 2018
Phase: Phase 4
Study type: Interventional

Randomized, placebo controlled trial evaluating the effect of acetazolamide on lung water content by ultrasound in lowlanders older than 40 years travelling from 760 m to 3'100 m.

NCT ID: NCT03537924 Recruiting - Altitude Hypoxia Clinical Trials

Effect of Acetazolamide on Right Heart Function During Exercise in Lowlanders Older Than 40 Years at Altitude

Start date: June 1, 2018
Phase: Phase 4
Study type: Interventional

Randomized, placebo controlled trial evaluating efficacy of acetazolamide on right heart function during exercise in lowlanders older than 40 years travelling from 760 m to 3'100 m.

NCT ID: NCT03536520 Recruiting - Altitude Hypoxia Clinical Trials

Effect of Acetazolamide on Visuo-motor Learning in Lowlanders Older Than 40 Years at Altitude

Start date: June 1, 2018
Phase: Phase 4
Study type: Interventional

Randomized, placebo controlled trial evaluating the effect of acetazolamide on visuo-motor learning performance in lowlanders older than 40 years travelling from 760 m to 3'100 m.

NCT ID: NCT03536507 Recruiting - Altitude Hypoxia Clinical Trials

Effect of Acetazolamide on Sleep Disordered Breathing in Lowlanders Older Than 40 Years at Altitude

Start date: June 1, 2018
Phase: Phase 4
Study type: Interventional

Randomized, placebo controlled trial evaluating the effect of acetazolamide on sleep disordered breathing in lowlanders older than 40 years travelling from 760 m to 3'100 m.

NCT ID: NCT03536455 Recruiting - Altitude Hypoxia Clinical Trials

Effect of Acetazolamide on Maximal Exercise Performance in Lowlanders Older Than 40 Years at Altitude

Start date: June 1, 2018
Phase: Phase 4
Study type: Interventional

Randomized, placebo controlled trial evaluating the effect of acetazolamide on maximal exercise performance in lowlanders older than 40 years travelling from 760 m to 3'100 m.

NCT ID: NCT03536429 Recruiting - Altitude Hypoxia Clinical Trials

Effect of Acetazolamide on Postural Control in Lowlanders Older Than 40 Years at Altitude

Start date: June 1, 2018
Phase: Phase 4
Study type: Interventional

Randomized, placebo controlled trial evaluating the effect of acetazolamide on postural control in lowlanders older than 40 years travelling from 760 m to 3'100 m.

NCT ID: NCT03390387 Recruiting - Clinical trials for Childhood Acute Lymphoblastic Leukemia

Childhood Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2015 (ALL-MB 2015)

ALL-MB 2015
Start date: November 2015
Phase: N/A
Study type: Interventional

QUESTIONS AND OBJECTIVES OF ALL-MB 2015 STUDY 1. Will the new risk group stratification (especially of T-ALL) to improve overall and event-free survival? 2. Will the new protocol is effective and feasible in patients older than 15 years, and especially in young adults? 3. Whether the intermittent dexamethasone administration in induction will result in a decrease in toxicity and mortality without loss of efficacy? 4. Whether the methylprednisolone administration as basic glucocorticoids during induction, consolidation and maintenance therapy will lead to decrease of severe infections and early mortality rate, improve survival and therapy compliance in adolescents and young adults with B-precursor ALL? 5. Whether the administration of Bortezomib in patients with B-precursor ALL with initial WBC≥100,000/µl will improve treatment outcome? 6. Whether the administration of Idarubicin instead Daunorubicin in low-risk T-ALL patients and two-phase induction in intermediate-risk T-ALL patients will reduce relapse rate and improve survival?